rexaceract
GT-02287 Small Molecule Target: GCase, glucocerebrosidase, GBA1
Gain Therapeutics
Most recent annual filing: 2026-03-15
- GT-02287 Ph2 start3Q 2026GT-02287 Ph2 start, 3Q 2026, material
- GT-02287 Ph2 toplinelate 2026/2027GT-02287 Ph2 topline, late 2026/2027, major
- GT-02287 Ph1 readoutOct 2026GT-02287 Ph1 readout, Oct 2026, notable
- Cash runway guidance update2Q 2027Cash runway guidance update, 2Q 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (5 active programs)
Technology platforms
Magellan · Minoryx Therapeutics
Computational target and drug discovery platform using AI-driven structure-based virtual screening to identify novel allosteric binding sites on disease-implicated proteins and discover proprietary small molecule structurally targeted allosteric regulators (STARs). Disease focus areas include CNS disorders, lysosomal storage disorders, metabolic disorders, and oncology.
Magellan
Proprietary allosteric drug discovery platform enabling identification of novel small molecule modulators that restore or disrupt protein function; disease focus includes neurodegenerative diseases, rare genetic disorders (lysosomal storage disorders), and oncology
Targets: GCase, β-galactosidase
Biotech Distilled coverage (11)
- 2026-08-12 UPDATE: Gain Therapeutics (GANX) - Day 360 Durability, and a $13.1M Problem 🔒 Paid
- 2026-07-16 UPDATE: Gain Therapeutics (GANX) - The Shareholder Letter, The Rebrand, and the CMO Exit
- 2026-06-29 UPDATE: Gain Therapeutics (GANX) - The FDA Clears the IND 🔒 Paid
- 2026-05-26 UPDATE: Gain Therapeutics (GANX) - The Stratification Gap Just Narrowed 🔒 Paid
- 2026-05-12 UPDATE: Gain Therapeutics (GANX) — The Dilution Engine Hums On, The Clock Keeps Ticking 🔒 Paid
- 2026-03-27 UPDATE: Gain Therapeutics (GANX) - The 10-K Unveils the Dilution Engine... 🔒 Paid
- 2026-03-21 UPDATE: Gain Therapeutics (GANX) - The Update That Spooked the Market
- 2026-03-14 UPDATE: Gain Therapeutics (GANX) - The FDA Taps the Brakes 🔒 Paid
- 2026-02-07 UPDATE: Gain Therapeutics (GANX) - The "Missing" Data Has Been Found (And It Looks Pretty Good) 🔒 Paid
- 2025-12-22 UPDATE: Gain Therapeutics (GANX) – Explaining The Rebound After The CEO’s Defense
- 2025-12-19 Gain Therapeutics (GANX): Scientific Due Diligence for Lead and Pipeline Products
Articles open on Substack. Some deep dives are subscriber-only.